IRMD — IRadimed Corporation

Summary of IRadimed Corporation Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $22 million, a 13% increase from $19.5 million in Q1 2025.
• Operating Income: $7.2 million, up 33% year-over-year.
• Net Income: $5.8 million, or $0.45 per diluted share, a 22% increase from the prior year.
• Gross Profit: $16.8 million with a gross margin of 77%, slightly up from 76% in Q1 2025.
• Cash Flow from Operations: $8.3 million, a 93% increase compared to $4.3 million in Q1 2025.
• Cash and Cash Equivalents: $56.4 million at the end of the quarter.
• Quarterly Dividend Declared: $0.20 per share, payable on May 29, 2026.

2. Strategic Updates and Business Highlights:

• Strong revenue contributions from the MRI-compatible IV infusion pump (3860) and patient monitoring systems.
• Introduction of the new 3870 MRI IV pump, with initial orders showing a higher average selling price (ASP) than anticipated (20% increase vs. expected 10-14%).
• Notable shift towards Quad systems, with over half of initial orders for four-channel configurations, indicating increased customer demand for more capacity.
• Focus on replacing an aging installed base of 3860 pumps, with a target of adding 1,000 replacement channels per year, in addition to existing sales.

3. Forward Guidance and Outlook:

• Q2 2026 Revenue Guidance: Expected between $20 million and $21 million.
• Full Year 2026 Revenue Guidance: Reaffirmed at $91 million to $96 million.
• Earnings Per Share Guidance: GAAP diluted EPS of $1.90 to $2.05 and non-GAAP diluted EPS of $2.06 to $2.21 for the full year.
• Anticipated gradual ramp-up in production of the 3870 pump, with plans to ship 130-135 units in Q2 and increase production in subsequent quarters.

4. Bad News, Challenges, or Points of Concern:

• Q2 revenue may not fully reflect the high level of order activity due to the transition from older 3860 systems to the new 3870, leading to a controlled revenue ramp rather than a step-change.
• The company is cautious in ramping up manufacturing to ensure quality, which could limit immediate revenue growth.
• The effective tax rate increased to approximately 25% due to timing of deductions, which may impact net income in the short term.

5. Notable Q&A Insights:

• Customers are increasingly opting for Quad systems, driven by the sales team’s close engagement and the new pump's design, which facilitates easier use of multiple channels.
• The company is prioritizing existing customer relationships over pursuing new greenfield opportunities for the time being, indicating a focus on maximizing the installed base replacement.
• Manufacturing ramp-up is being approached cautiously to stabilize supply chains and ensure product quality, with plans to significantly increase output in the latter half of 2026.

Overall, IRadimed's Q1 2026 results reflect strong growth and positive market reception for its new products, although challenges remain in transitioning from older systems and managing production ramp-up.